KRAS G12D

At this year's ASCO Annual Meeting, investigators also presented encouraging early clinical data for several KRASG12D-selective inhibitors, including RNK08594, GFH375, and DN022150, suggesting that this type of drug could play a role in the treatment of several solid tumors, such as pancreatic ductal adenocarcinoma and non-small cell lung cancer.

Our findings not only reveal a clinically relevant resistance mechanism to KRAS G12D inhibition but also provide a rational, effective combined strategy. Ultimately, the combination of HRS-4642 with nimotuzumab offers a promising therapeutic strategy for PDAC patients harboring KRAS G12D mutations, laying a foundation for advancing clinical research in overcoming resistance to KRAS G12D-targeted therapies.

Mouse embryonic fibroblasts transformed with KRASG12C also contain more saturated lipids than KRASG12D MEFs. Thus, activities of KRAS mutants depends on lipid acyl chain remodeling in an allele-specific manner.

Although recent advances have led to covalent inhibitors such as Sotorasib and Adagrasib for the KRAS G12C mutation, effective therapies for other common variants, particularly KRAS G12D, which is highly prevalent in aggressive pancreatic cancers, remain limited...To further validate the predictive capability of the models, two compounds identified as high-confidence candidates, Cobimetinib and Etrasimod, were selected for experimental evaluation...While additional biochemical and pathway-level studies are required to confirm direct target engagement, these results support the model's utility in prioritizing candidate compounds with allele-specific activity profiles. Overall, this study provides a data-driven framework for identifying potential KRAS-targeted therapies and highlights the value of integrating machine learning predictions with experimental validation.

Furthermore, as a proof-of-concept, the sensing paradigm reliably discriminated KRAS-mutant patients from healthy donors in clinical plasma samples, showing good agreement with PCR-based analysis. The ABINS strategy provides a simple amplification-coupled and label-free colorimetric approach for mutation-associated ctDNA analysis, while broader validation in larger clinical cohorts and more representative ctDNA models will still be needed to further define its practical performance.

Further exploration revealed that, while WFS1 is regulated by the MAPK and PI3K/AKT pathways in MRTX1133-sensitive cells, acquired resistance is associated with downregulation of the E3 ubiquitin ligase Smurf1, leading to increased WFS1 protein stability. Overall, these results highlight WFS1 as an adaptive factor and potential therapeutic target in KRASG12D-driven malignancies, offering a novel approach to enhance the efficacy of KRASG12D inhibitors and overcome acquired resistance.

P2, N=180, Recruiting, Verastem, Inc.

Combined MEK and autophagy inhibition showed limited tolerability in human PDAC. Divergent efficacy between preclinical and clinical settings likely reflects differences in tumor cell state heterogeneity between models. Integration of diverse, representative preclinical models is critical to guide development of effective therapies in PDAC.

Aging is a major risk factor for cancer, yet its role in cancer biology remains largely unexplored and often overlooked. Interestingly, studies assessing the impact of aging on oncogenic KrasG12D-driven lung tumor initiation, early progression, and metastasis have reported both pro- or antitumoral effects, which are presented and discussed herein.

The second approach illustrates how a syngeneic orthotopic transplantation model can be used to study target genes and pathways that influence the tumor microenvironment and immunogenic cell death in a two-week timeframe. Together, these methods provide reproducible and versatile tools to investigate how modulation of cell death pathways impacts lung cancer development and progression and affects the tumor immune microenvironment, thus providing important information to guide the development of novel therapeutic strategies in lung cancer.

Mechanistically, ERO1L enhances the protein expression of the chemokine CCL2 through its role in oxidative folding, thereby promoting the recruitment of macrophages. Thus, this study reveals that Kras mutation upregulates ERO1L to promote inflammation and pancreatic tumorigenesis, providing new insights and potential targets for the treatment of pancreatic cancer.

Invitae and Fulgent offer the broadest gene coverage (20/21), with 16 genes universally covered by all four providers, while GeneD and Prevention Genetics lag at 17 genes each, with critical gaps in rare cancer predisposition genes like TSC1, TSC2, and NF1. Overall, these findings refine the molecular landscape of PC and highlight key genes and pathways with potential clinical relevance.